The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
54 Pages Posted: 15 Jan 2009 Last revised: 28 Dec 2022
There are 2 versions of this paper
The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
Date Written: January 2009
Abstract
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug events by modeling the interaction between a welfare maximizing regulator (the FDA) and a profit maximizing firm. In our analysis demand is sensitive to both promotion and regulatory interventions. Promotion-driven market expansions enhance profitability yet may involve the risk that the drug would be prescribed inappropriately, leading to adverse regulatory actions against the firm. The model exposes the effects of the current regulatory system on consumer and producer welfare. Particularly, the emphasis on safety over benefits distorts the market allocation of drugs away from some of the most appropriate users. We then empirically test the relationship between drug promotion and reporting of adverse reactions using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and adverse drug reactions. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of adverse medical events for certain conditions.
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
The Effect of Prescription Drug Advertising on Doctor Visits
By Toshiaki Iizuka and Ginger Zhe Jin
-
What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?
-
Direct to Consumer Advertising and Prescription Choice
By Toshiaki Iizuka and Ginger Zhe Jin
-
Direct to Consumer Advertising and Prescription Choice
By Toshiaki Iizuka and Ginger Z. Jin
-
Direct-to-Consumer Advertising in Pharmaceutical Markets
By Kurt Richard Brekke and Michael Kuhn
-
By Rosemary J. Avery, Donald Kenkel, ...
-
Drug Advertising and Health Habit
By Toshiaki Iizuka and Ginger Zhe Jin
-
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs
By Paul H. Rubin and Adam Atherly
-
Mitigating Agency Problems by Advertising, with Special Reference to Managed Health Care
By Paul H. Rubin and Joel L. Schrag